Pertuzumab for the treatment of ovarian cancer

Expert Opinion on Biological Therapy

Volumn 10, Issue 7, 2010, Pages 1113-1120

  Langdon, Simon P ^a   Faratian, Dana ^a   Nagumo, Yoko ^b   Mullen, Peter ^a   Harrison, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Gemcitabine; HER3 expression; Ovarian cancer; Pertuzumab

Indexed keywords

CANERTINIB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEMCITABINE; LAPATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PERTUZUMAB; PLACEBO; PLATINUM COMPLEX; PROTEIN KINASE B; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953343321     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.487062     Document Type: Review

References (36)

1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;10:167-181
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin 2008;58:71-96
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488
4. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003;90:593-606
5. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinumand paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88:266-269 (Pubitemid 36331977)
6. Agarwal R, Kaye S. Ovarian cancer: strategies to overcome resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516
7. Palayejkar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008;18:879-890
8. Badache A, Hynes NE. A new therapeutic antibody masks erbB2 to its partners. Cancer Cell 2004;5:299-301
9. Langdon SP, Mullen P, Faratian D, et al. Pertuzumab. Drugs Future 2008;33:1-8
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137
11. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354
12. Moasser MM. The oncogene HER2: its signalling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-6487
13. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors is a mediator of lateral signalling. EMBO J 1997;16:1647-1655
14. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-760
15. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
16. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091
17. Meden H, Marx D, Rath W. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994;13:45-53
18. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137
19. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11:5300-5309
20. Jackson JG, St Clair P, Sliwkowski MX, et al. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004;64:2601-2609
21. Mullen P, Cameron DA, Hasmann M, et al. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalling. Mol Cancer Ther 2007;6:93-100
22. Takai N, Jain A, Kawamata N, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005;104:2701-2708
23. Makhija S, Amler LC, Glenn D, et al. Clinical Activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-1223
24. Nagumo Y, Faratian D, Mullen P, et al. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res 2009;7:1563-1571
25. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-2543
26. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-4332
27. Kaye SB, Poole CJ, Bidzinksi M, et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin based therapy alone in patients with relapsed,platinum sensitive ovarian cancer [abstract 5520]. J Clin Oncol 2008;26(Suppl):305s
28. ASCO Media Player. Available at: http://media.asco.org/silver/ AstuteMediaPlayer.aspx?ConferenceID= 55&TrackID=5&SessionID=392& PresentationID=11974&Token [Last accessed 28 April 2010]
29. Hudis CA. Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
30. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-290
31. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313
32. Rivkin SE, Muller D, Iriarte D, et al. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J Clin Oncol 2008;26:5556
33. Kimball KJ, Numnum TM, Kirby TO, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008;111:95-101
34. Campos S, Hamid O, Seiden MV, et al. Multicenter randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005;23:5597-5604
35. Balsega J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144
36. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-9336